N
CERE

Natixis’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Natixis’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-71,789
Closed -$2.94M – 1161
2024
Q2 		$2.94M Hold
71,789
– – 0.02% 357
2024
Q1 		$3.03M Sell
71,789
-48,906
-41% -$2.05M 0.02% 378
2023
Q4 		$5.12M Buy
+120,695
New +$3.47M 0.04% 291

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Natixis's CERE Position: Q3 2024 in Review

Natixis sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 71,789 shares — an estimated $2.94M sold.

Natixis first reported a position in CERE in Q4 2023 and held it in 3 quarters. The position peaked at $5.12M in Q4 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Natixis reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Natixis sold 71,789 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $2.94M.
  • Natixis first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 3 quarters.
  • Natixis's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $5.12M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Natixis's 13F filing for Q3 2024, filed 13 Nov 2024.